- Home
- BRW vs CERS Comparison
BRW vs CERS Comparison
Compare BRW & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRW | CERS |
|---|---|---|
| Founded | 1987 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.8M | 276.0M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | BRW | CERS |
|---|---|---|
| Price | $7.06 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 222.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 15.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $199,191,000.00 |
| Revenue This Year | N/A | $25.31 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.03 |
| 52 Week Low | $7.15 | $1.12 |
| 52 Week High | $8.30 | $2.25 |
Technical Indicators
Market Signals| Indicator | BRW | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 61.04 |
| Support Level | $7.11 | $1.83 |
| Resistance Level | $7.16 | $2.25 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 11.54 | 63.79 |
Price Performance
Historical ComparisonAbout BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.